B+
Bull case
25%
Probability
Target price
$25.00
+18.8% vs current
DOCS
DoximityFNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$20.50
-2.6% vs current
B-
Bear case
30%
Probability
Target price
$14.50
-31.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+41.3
Score
AI commentary
Post-earnings tone is negative and revision-driven. The May 13, 2026 release showed solid cash generation and engagement, but the market focused on slower FY27 growth and lower EBITDA guidance. By May 14-15, 2026, BTIG had downgraded the stock and several firms had cut targets, while the shares had reset to $18.97 by the May 15 close. The packet has no usable social-coverage signal, so confidence should stay moderate rather than aggressive.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-13eventPost-earnings guidance reset reframed the storyHigh impact
The May 13, 2026 earnings release showed Q4 revenue of $145.4M, up 5% y/y, but FY27 guidance reset lower to $664M-$676M revenue and $323M-$335M adjusted EBITDA, while management highlighted record workflow engagement and accelerating clinical AI usage [#8-K-2026-05-13].
2026-08-07catalystQ1 FY27 print is the first test of the new floorHigh impact
Management guided June-quarter revenue to $151M-$152M and adjusted EBITDA to $68.5M-$69.5M [#8-K-2026-05-13]. A clean beat could stabilize sentiment after the reset, while another soft demand read would reinforce the de-rating.
2026-11-15catalystAI and workflow partnerships need to convert into durable monetizationHigh impact
Management cited over 800,000 active prescribers using workflow tools in Q4, nearly half using clinical AI, plus new Aledade and Photon partnerships [#8-K-2026-05-13]. The longer-duration upside case depends on those usage gains showing up in renewed growth rather than just higher investment.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology